Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Aurinia Pharmaceuticals Inc. (AUPH) has a Wall Street consensus price target of $15.50, based on estimates from 14 covering analysts. With the stock currently trading at $14.17, this represents a potential upside of +9.4%. The company has a market capitalization of $1.88B.
Analyst price targets range from a low of $15.00 to a high of $16.00, representing a 6% spread in expectations. The median target of $15.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, AUPH trades at a trailing P/E of 6.8x and forward P/E of 16.9x. Analysts expect EPS to grow -59.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $11.80, with bear and bull scenarios of $-3565.85 and $10.72 respectively. Model confidence stands at 38/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how AUPH stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus price target for AUPH is $15.5, close to the current price of $14.17 (9.4% implied move). Based on 14 analyst estimates, the stock appears fairly valued near current levels.
AUPH has a consensus rating of "Buy" based on 14 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $15.5 implies 9.4% upside from current levels.
With a forward P/E of 16.869x, AUPH trades at a relatively low valuation. The consensus target of $15.5 implies 9.4% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $16 for AUPH, while the most conservative target is $15. The consensus of $15.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $11 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
AUPH is moderately covered, with 14 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month AUPH stock forecast based on 14 Wall Street analysts shows a consensus price target of $15.5, with estimates ranging from $15 (bear case) to $16 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $12, with bear/bull scenarios of $-3566/$11.
Our quantitative valuation model calculates AUPH's fair value at $12 (base case), with a bear case of $-3566 and bull case of $11. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 38/100.
AUPH trades at a forward P/E ratio of 16.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 6.8x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
AUPH appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $15.5 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
AUPH analyst price targets range from $15 to $16, a 6% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $15.5 consensus represents the middle ground. Our model's $-3566-$11 range provides an independent fundamental perspective.